PROCEPT BioRobotics (PRCT) Cash & Equivalents (2020 - 2026)

PROCEPT BioRobotics (PRCT) has reported Cash & Equivalents for 7 consecutive years, with $245.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 22.32% year-over-year to $245.6 million; the TTM figure through Mar 2026 stood at $245.6 million (down 22.32% YoY), while the FY2025 annual figure was $275.1 million, down 17.57% from the prior year.
• Cash & Equivalents declined to $245.6 million in Q1 2026 per PRCT's latest filing, from $275.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $333.7 million in Q4 2024 and bottomed at $149.7 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $253.2 million across 5 years, with a median of $257.2 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 230.11% — and 2023, when it tumbled 44.52%.
• PROCEPT BioRobotics' Cash & Equivalents stood at $221.9 million in 2022, then rose by 15.94% to $257.2 million in 2023, then rose by 29.74% to $333.7 million in 2024, then fell by 17.57% to $275.1 million in 2025, then dropped by 10.7% to $245.6 million in 2026.
• Business Quant data shows PRCT's Cash & Equivalents at $245.6 million in Q1 2026, $275.1 million in Q4 2025, and $294.3 million in Q3 2025.